What we are looking for
At Roche we are looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionise the standard of care. We focus on our main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, we always look for the right partnership and cultural fit.
We are not looking for compounds that represent marginal improvements compared to the current standard of care. Roche is not interested in biosimilar compounds or compounds that do not have the potential to become first-in-class or best-in-class.
Please click below for more detailed information on what we are looking for:
- Oncology and Immuno-oncology
Innovation is at the core of Roche’s leading position in oncology. The emphasis lies on systems biology, biotechnology, translational medicine, biomarkers, modeling and simulation to drive and deliver world class life science and ultimately novel therapeutics to patients in need. With Roche colleagues from Pharma and Diagnostic Divisions, Roche Oncology is focused on bringing new, medically significant therapies through the implementation or Roche’s Personalised Healthcare strategy.
Thanks to our oncology footprint in our numerous sites – from Penzberg, Germany to Schlieren, Switzerland and SSF, USA, Roche Oncology focuses on continuing the pioneering biotechnology work and tradition established more than 30 years ago including therapeutic antibodies, antibody conjugates, engineered antibodies, small molecules and the new expanding area of cancer immunotherapy.
Roche Partnering is exploring external innovation and emerging technologies to create sustainable, value adding industry partnerships. We are actively looking for partners to bring in the first- and best-in-class therapeutics in the fields of angiogenesis, antibody conjugates and therapeutic antibodies. In the expanding field of cancer immunotherapy we are looking for therapeutic modalities such as antibodies, small molecules and cancer vaccines to complement and synergize with the existing pipeline in the modulation of the tumor microenvironment, in providing tumor targeted immunomodulation and ultimately engineer a systemic modulation of immunity against cancers.
Our strategy in ophthalmology focuses on sight robbing “back of the eye” diseases. They include: Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME)
Dry AMD and related Geographic Atrophy (GA) make up over 90% of AMD cases but have no currently approved therapy. The scientists at Roche are committed to the development of therapy for these retinal diseases and seek drug candidates with neuro-protective and retinal epithelial preserving properties. In addition, we also actively seek novel therapies for the wet form AMD, Diabetic Macular Edema, and other related diabetic retinal complications that would complement our Lucentis (ranibizumab) franchise.
Other diseases where we have a more opportunistic approach include Retinitis of Prematurity, Retinitis Pigmentosa, Uveitis, and Dry Eye. In Glaucoma we are particularly interested in therapies that have demonstrated the ability to protect retinal neurons compared to intraocular pressure lowering therapies.
If you have a promising drug candidate in ophthalmology, why not submit your idea, meet us at a conference or contact email@example.com, Head of Infectious Diseases / Inflammation/ Specialty care / Ophthalmology.
- Infectious Diseases
In infectious diseases, our focus is specifically on Hepatitis B (HBV), influenza and antibacterials. For Hepatitis B we are looking for any products or therapeutic strategies for promoting durable seroconversion.
While these indications are key to Roche, we are also on the lookout for innovative, best-in-class treatments for chronic or non-chronic viral infections of high unmet need such as Human Papilloma Virus (HPV), HIV and respiratory infections. In every case, we prioritise products with robust clinical proof of concept and/or clinical differentiation from more advanced treatment options.
If you have a promising drug candidate in infectious diseases, why not submit your idea, meet us at a conference or contact firstname.lastname@example.org, Head of Infectious Diseases / Inflammation/ Specialty care / Ophthalmology.
We have several strategic focus areas for neuroscience partnering. These are: Alzheimer’s Disease (AD), Parkinson’s disease and other neurodegenerative disorders; multiple sclerosis (MS), schizophrenia, autism spectrum disorders (ASD) and treatment-resistant depression.
We are particularly interested in programmes against priority targets and pathways even where these are early stage with preclinical proof of concept and with suitable physical characteristics of the compound.
We are open to treatments that are either disease modifying or have a superior impact on cognition compared with existing treatments.
In MS we are looking for therapies offering the prospect of remyelination. Current therapies impact too much on immune function and have not addressed fatigue or the cognitive problems associated with disease progression in MS. We are therefore looking for oral or biologic disease modifying compounds that improve cognition or reduce fatigue without impacting on immune function and ameliorating symptoms.
Schizophrenia is a condition with established therapeutics for stage one disease but very little available for the negative symptoms in chronic disease which include apathy, blunted emotion and depression. There have been recent advances in the understanding of disease pathology and we are interested in oral or biologic compounds that have agents which address unmet medical need and positive residual symptoms and PHC approaches enabling better patient stratification.
ASD constitutes a spectrum of heterogeneous types including Autism, Asperger’s Syndrome and Pervasive Developmental Disorder– for which no current therapies have been found. Our focus is currently in fragile X and ASD and we remain open to evaluation therapeutics impacting synaptic morphology or resulting in improvement of core symptoms. We also have an interest in pediatric neuromuscular diseases, such as SMA and muscular dystrophy.
While there have been significant advances in understanding the treatment of depression in recent years there is little that can presently be done for the many patients who do not benefit from existing therapeutic interventions. We are looking for oral or biologic compounds that can improve patient functioning in chronic treatment resistant depression.
We remain opportunistic in areas such as attention-deficit hyperactivity disorder (ADHD), Bipolar disease, Obsessive-compulsive disorder (OCD) and would typically require evidence of a clinical signal before further evaluating in these indications.
- Early-stage collaborations
To access new breakthroughs and explore ways in which we can use them for the benefit of patients, we have created an independent network of research and development centres. Extending the Innovation Network (EIN) is a unique programme within Roche that focuses on tapping into early innovation from academic and research centres.
A partnership model with mutually beneficial relationships - where academia provides innovative thinking and entrepreneurial spirit and Roche provides expertise and commercial know-how to move towards drug development - has already proven successful.
If you are interested in an early-stage collaboration, why not submit your idea, meet us at a conference or contact email@example.com, Head Science in Academia / Neglected Disesases or firstname.lastname@example.org, Head of Venture & Innovation
- Research and Technologies
Roche has been at the forefront of collaborations with academic research centres and biotechnology companies in order to identify early-stage opportunities and technologies that have the potential to revolutionise the standard of care. We look for collaborations to reinforce our R&D capabilities, in particular in:
- Small Molecules: chemical biology approaches for new target discovery, in-silico technologies
- Biologics: antibody diversity, bi-specific antibodies, BBB transcytosis, alternative scaffolds, cancer antigens, immunotoxins
- Peptides: cell penetration, multi-pharmacology, intrinsic oral bioavailability, tissue targeting, half-life extension
- Targeting therapeutics: Next generation ADCs, targeted delivery systems, novel payloads, site specific activation technologies to target particular tissue and cell types
- Drug delivery and formulation: topical and sustained ocular delivery, cancer immunotherapy delivery
- Healthcare IT: Mobile applications and digital health solutions to aid therapeutic clinical development and commercialization
- Nonclinical Safety: predictive tools for immunogenicity and toxicology, 3D-cell models, toxicogenomics
- Translational Medicine: biomarker technologies including imaging
We are also interested in delivery of drug products to the subcutaneous site.
Within the organisation, the Strategic Partnering team evaluates a range of deal types including mergers and acquisitions (M&A); alliances covering more than one therapeutic area; out partnering of late stage assets; and in-licensing opportunities that do not fall within Roche’s key therapy areas of interest.
The Strategic Partnering team works closely with Disease Therapy Area heads, to provide expertise on M&A deals.